Tom Brown

Mar 15, 2017

Tom Brown joined the board of Accelerate Diagnostics on March 14. Brown started his career at Abbott Laboratories Diagnostics Division and retired in 2002 as president of the division. He currently is on the board of Quidel and Stericycle. 

More Like This

Dec 12, 2018

Melissa Lueke, Eric Rasmussen, Bryan Baldasare

Executive Vice President and Chief Financial Officer at Meridian Bioscience, Melissa Lueke, will retire from her position effective January 1, 2019. Lueke, who has been at Meridian for 20 years, will remain with the firm in a paid financial consulting role with a renewable contract of three years.

Meridian also promoted Eric Rasmussen from his role as EVP of Corporate Development to the position of EVP, CFO, and Principal Financial Officer, also effective January 1, 2019. Rasmussen was hired by Meridian in June of 2018, and previously served in corporate development and financial leadership roles at Lear Corporation, an automotive seating and electrical systems supplier. Rasmussen has also served on the advisory board of Exploragen, a DNA lifestyle company.

Meridian has also promoted Bryan Baldasare to the role of Chief Accounting Office. Baldasare has been with Meridian since 2000, and most recently served as Senior Vice President, Corporate Controller and Treasurer.

Dec 11, 2018

Catherine Friedman, Alex Aravanis

Grail has appointed Catherine Friedman as chair of the firm's board of directors. Friedman succeeds Bill Rastetter, who will continue to serve as a director of the firm's board. Friedman joined the board in July 2017. She previously held numerous executive positions during an investment banking career with Morgan Stanley, including managing director head of West Coast Healthcare, and co-head of the biotechnology practice. Friedman is also a board member at Altaba, Radius Health, and Lyell Immunopharma.

Grail has also appointed Alex Aravanis as Chief Scientific Officer and head of research and development. Aravanis is a cofounder of Grail. Prior to being CSO, Aravanis served as VP of research and development. He previously served as senior director of research and development for Illumina. In addition, Aravanis served as VP of development and CSO of Sapphire Energy and was a cofounder and VP of engineering of Pria Diagnostics.

Dec 11, 2018

Hans Clevers

The board of directors of Roche Holding has proposed Hans Clevers as a new board member. He is scheduled to be elected to the board at the company's annual general meeting on March 5, 2019. Clevers is a professor of molecular genetics at the University Medical Center Utrecht in the Netherlands.

Dec 10, 2018

Daniel O'Day, William Anderson

Daniel O'Day will leave his post as CEO and corporate executive committee member of Roche Pharmaceuticals at the end of December to become CEO and board chairman of Gilead Sciences, effective March 1, 2019.

In the interim period, he will provide support to Roche to ensure a smooth transition to his successor, William Anderson, who will become CEO of Roche Pharmaceuticals effective January 1, 2019. Anderson is currently CEO of Roche-owned Genentech, which he joined in 2006. In previous roles, he led Genentech's immunology business unit, headed oncology sales and marketing, and led global product strategy. Anderson holds a master of science degree in management and chemical engineering from MIT.

Dec 10, 2018

Prahlad Singh

Prahlad Singh has been appointed president and COO of PerkinElmer, effective Jan. 1, 2019. Singh will be responsible for the Discovery and Analytical Solutions and the Diagnostics operating divisions. PerkinElmer said the change is being made to "better facilitate synergies across the businessess to identify incremental growth opportunities, create operating efficiencies, and most importantly, accelerate the pace of innovation across the company." He joined PerkinElmer in 2014 as president of the diagnostics business and was elected an officer in 2016 and executive vice president in 2016. Prior to joining the firm, Singh was GM of GE Healthcare's women's health business, and before that he held senior executive level positions in strategy, business development, and M&A at GE and at Philips Healthcare. 

Dec 10, 2018

Bradley Cole

Castle Biosciences announced Bradley Cole has been appointed to its board. Cole is the CFO of Genomic Health and has more than 30 years of experience in finance and operations in the diagnostics and life sciences industries. He also has served as COO of Genomic Health. Prior to joining the firm, he was VP of finance and business development for the endovascular solutions group at Guiidant, and was VP and GM of vascular surgery business unit of Guidant. 

Nov 30, 2018

Joan Martin

Joan Martin has joined Ortho Clinical Diagnostics as vice president of Europe, the Middle East, and Africa. He will be in charge of the company's commercial operations in the region. Martin was previously executive vice president and head of Europe, the Middle East, and Africa at Accelerate Diagnostics. 

Nov 26, 2018

Reginald Seeto

CareDx has appointed Reginald Seeto to the newly created role of president and chief business officer. Seeto has 20 years of experience in commercial operations, corporate development, and strategy, most recently serving as chief operating officer at Ardelyx. He has also worked at AstraZeneca/Medimmune and was a member of the MedImmune executive team. His responsibilities there included leading corporate development and strategy, global strategic marketing, and portfolio management for all therapeutic areas, as well as a country leadership role at AstraZeneca in Thailand. Before AstraZeneca, Seeto held positions at Organon Biosciences and at McKinsey.

Nov 19, 2018

Jason Ryan

Jason Ryan will leave his post as CFO of Foundation Medicine to become chief operating and financial officer at Magenta Therapeutics, effective January 1 of 2019. Prior to joining Foundation Medicine, he held management positions for Taligen Therapeutics, Codon Devices, and Genomics Collaborative. Ryan holds a BS in economics from Bates College and an MBA from Babson College. Foundation Medicine has not announced a successor for Ryan yet.

Nov 13, 2018

Steve Ziganti, Patrik Jeanmonod, Jack Ball, Allen Poirson

Cytek Biosciences announced Steve Ziganti has joined the firm as vice president of worlwide sales and Patrik Jeanmonod has been hired as the company's chief financial officer. 

Additionally, Jack Ball and Allen Poirson have joined Cytek's board of directors. 

Ziganti was previously VP of sales and service at BD Biosciences before retiring from that firm. Jeanmonod has previously held executive positions in finance at Covance, Bridge Pharmaceuticals, and Synteract. He is currently a board member at Seal Biosciences. 

Ball formerly was the CEO of Amnis and CCO of Accuri Cytomers and Molecular Probes. Poirson is a partner at Mighty Capital and previously was CEO of Sony Biotechnology.

Nov 08, 2018

Jim Mullen

Jim Mullen has been elected to the board of directors of Thermo Fisher Scientific, bringing the total number of board members to 12. Previously, he was the CEO of Patheon, which Thermo Fisher acquired last year. Prior to that, he was the president and CEO of Biogen Idec. Mullen holds a bachelor of science degree in chemical engineering from Rensselaer Polytechnic Institute and a master's degree in business from Villanova University.

Nov 07, 2018

Scott Nicholson, Cory Dunn

Biocept has appointed Scott Nicholson as its Vice President of Sales in the US and Cory Dunn as its Vice President of Marketing. Nicholson has 24 years of experience in the medical laboratory industry with a focus in oncology for the physician and hospital markets. He has served as a sales manager, executive, district manager, and regional manager in prior positions. Most recently, Nicholson was vice president of sales at GenomeDx, where he led the commercialization effort for the firm's Decipher tests.

Dunn has over 15 years of commercial marketing experience, specializing in diagnostic testing services for oncology. She most recently served as VP of commercial marketing at GenomeDx, where she led the launch, commercial marketing, and product life cycle management of the Decipher suit of tests. Prior to GenomeDx, Dunn oversaw the marketing efforts for Plus Diagnostics' Gastroenterology, Dermatology and Hematology-Oncology product lines. She holds post graduate science and education degrees from the University of California, San Diego and Stanford University, respectively.

In connection with the hirings, Biocept said it granted each individual an inducement stock option award to purchase 24,200 shares of Biocept common stock, with an exercise price per share equal to the closing price of Biocept's common stock on October 31, 2018.

Nov 05, 2018

Hillel Kahane

Acupath Laboratories has announced the appointment of Hillel Kahane as the company's chief medical officer and director of uropathology. Previously, Kahane served as medical director of Bostwick Labs from 2007 to 2018 and as executive medical director of Dianon Pathology, a Laboratory Corporation of America subsidiary, from 2000 to 2007. Kahane will join Acupath Chief Sales Officer John Cucci, Chief Financial Officer Zaleena Neice, and Chief Operating Officer Steve Kamalic on the Accupath Labs Executive Committee to help guide the company's overall strategy and vision.

Nov 05, 2018

Oved Amitay

Centogene has appointed Oved Amitay its chief business officer. He has almost 30 years of commercial and development experience with a focus on orphan drugs for patients with rare genetic diseases. Amitay joins Centogene from Arrett Neuroscience where he was president and COO. Prior to that he was VP, head of commercial at Alnylam Pharmaceuticals. 

Nov 02, 2018

Peter Collins

Peter Collins has stepped down as chief business officer and director of Premaitha Health, effective November 1. Previously, he was vice president and head of diagnostics at GlaxoSmithKline.